Drug
Interferon alpha-2b
Interferon alpha-2b is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
50%
Ph phase_2
1
17%
Ph phase_3
2
33%
Phase Distribution
3
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
4 of 6 finished
Non-Completion Rate
33.3%
2 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(4)
Terminated(2)
Detailed Status
Completed4
Withdrawn2
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 13 (50.0%)
Phase 21 (16.7%)
Phase 32 (33.3%)
Trials by Status
withdrawn233%
completed467%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_1
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
NCT01603212
completedphase_1
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
NCT00629200
withdrawnphase_3
Randomized Phase III of PRRT Versus Interferon
NCT01860742
withdrawnphase_2
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
NCT00293527
completedphase_3
Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
NCT00273247
Clinical Trials (6)
Showing 6 of 6 trials
NCT01603212Phase 1
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
NCT00629200Phase 1
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
NCT01860742Phase 3
Randomized Phase III of PRRT Versus Interferon
NCT00293527Phase 2
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
NCT00273247Phase 3
Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
NCT00234182Phase 1
Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6